Medicinal Chemistry, Janssen Research & Development , Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain.
J Med Chem. 2012 Oct 25;55(20):8685-99. doi: 10.1021/jm300912k. Epub 2012 Oct 11.
The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines, which were conveniently radiolabeled with carbon-11, as potential positron emission tomography (PET) radiotracers for in vivo imaging of the allosteric binding site of the metabotropic glutamate (mGlu) receptor subtype 2 are described. The synthesized compounds proved to be potent and selective positive allosteric modulators (PAMs) of the mGlu receptor 2 (mGluR2) in a [³⁵S]GTPγS binding assay and were able to displace an mGluR2 PAM radioligand, which we had previously developed, with IC₅₀ values in the low nanomolar range. The most promising candidates were radiolabeled and subjected to biodistribution studies and radiometabolite analysis in rats. Preliminary small-animal PET (μPET) studies in rats indicated that [¹¹C]20f binds specifically and reversibly to an mGluR2 allosteric site, strongly suggesting that it is a promising candidate for PET imaging of mGluR2 in the brain.
描述了一系列新型 7-(苯哌啶基)-1,2,4-三唑并[4,3-a]吡啶的合成及其与碳-11 的体外和体内评价,这些化合物可方便地进行放射性标记,作为代谢型谷氨酸(mGlu)受体亚型 2 变构结合部位的体内成像的正电子发射断层扫描(PET)放射性示踪剂。在 [³⁵S]GTPγS 结合测定中,合成的化合物被证明是 mGlu 受体 2 (mGluR2) 的有效和选择性正变构调节剂(PAM),并且能够以低纳摩尔范围的 IC₅₀ 值置换我们之前开发的 mGluR2 PAM 放射性配体。最有前途的候选物被放射性标记,并在大鼠中进行了生物分布研究和放射性代谢产物分析。在大鼠中的初步小动物 PET (μPET) 研究表明,[¹¹C]20f 特异性和可逆转地结合到 mGluR2 变构位点,强烈表明它是大脑中 mGluR2 PET 成像的有前途的候选物。